DRUG SUBSTITUTION POLICIES: ARE THEY INTERCHANGEABLE GENERICS AND BIOSIMILARS? UNFAVORABLE ASPECTS

被引：0
|
作者：
Horga, J. F. [1 ]
机构：
[1] Hosp Gen Univ, Unidad Farmacol Clin, Alicante, Spain
来源：
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY | 2012年 / 111卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：5 / 5
页数：1
相关论文
共 18 条
  • [1] Substitution of biosimilars compared to generics and hybrids
    Chemtob, Marie-Catherine Conce
    MEDECINE & DROIT, 2024, 2024 (187): : 67 - 72
  • [2] The Automatic Substitution of Biosimilars: Definitions of Interchangeability are not Interchangeable
    Anita Afzali
    Daniel Furtner
    Richard Melsheimer
    Philip J. Molloy
    Advances in Therapy, 2021, 38 : 2077 - 2093
  • [3] The Automatic Substitution of Biosimilars: Definitions of Interchangeability are not Interchangeable
    Afzali, Anita
    Furtner, Daniel
    Melsheimer, Richard
    Molloy, Philip J.
    ADVANCES IN THERAPY, 2021, 38 (05) : 2077 - 2093
  • [4] KNOWLEDGE AND ATTITUDE OF COMMUNITY PHARMACY EMPLOYEES TOWARDS AN AUTOMATIC DRUG SUBSTITUTION OF GENERICS AND BIOSIMILARS
    Lukasik, Zuzanna Malgorzata
    Nowicki, Michal
    ACTA POLONIAE PHARMACEUTICA, 2018, 75 (05): : 1247 - 1254
  • [5] BIOSIMILARS: LIMITATIONS FOR THE USE OF SUBSTITUTION POLICIES
    Avendano-Sola, C.
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2012, 111 : 6 - 6
  • [6] IMPACT OF GENERICS AND BIOSIMILARS ON BRANDED DRUG LISTING DECISIONS IN SINGAPORE
    Lim, S.
    Koh, V
    Yoshino, M.
    Rooney, Brooks C.
    VALUE IN HEALTH, 2019, 22 : S796 - S796
  • [7] Increases in Drug Utilization and Patent Expirations: A Recipe for Growth of Generics' Market Share, despite Stalling on Biosimilars
    Buffery, Dalia
    AMERICAN HEALTH AND DRUG BENEFITS, 2009, 2 (06): : 294 - 294
  • [8] A review of patient perspectives on generics substitution: what are the challenges for optimal drug use
    Hakonsen, Helle
    Toverud, Else-Lydia
    GABI JOURNAL-GENERICS AND BIOSIMILARS INITIATIVE JOURNAL, 2012, 1 (01): : 28 - 32
  • [9] Challenges of developing generics substitution policies in low- and middle-income countries (LMICs)
    Hassali, Mohamed Azmi
    Wong, Zhi Yen
    GABI JOURNAL-GENERICS AND BIOSIMILARS INITIATIVE JOURNAL, 2015, 4 (04): : 171 - 172
  • [10] OTHER ASPECTS OF DRUG POLICIES - COMMENT
    KATHOLNIGG, O
    KRIMINALISTIK, 1991, (11): : 737 - 738
12